GLAS vs KNSA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: GLAS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GLAS and KNSA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GLAS and KNSA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Glass House Brands is a vertically integrated cannabis company headquartered in Long Beach, California, that reports across three segments: Wholesale Biomass (selling bulk cannabis flower and trim), Retail (its own dispensaries), and Cannabis-Related Consumer Packaged Goods (its branded products). Its defining asset is massive greenhouse cultivation capacity, anchored by a large SoCal Farm, that lets it grow cannabis at a low cost per pound relative to indoor growers. The strategy is scale and cost leadership: produce enormous volumes of biomass cheaply, sell into the California wholesale market, and layer higher-margin brands and retail on top. Wholesale biomass has recently made up the majority of revenue, and the company has been expanding planted acreage and building out additional greenhouse capacity.

Full GLAS guide

Kiniksa Pharmaceuticals (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company focused on immune-modulating and cardiovascular therapies. Its franchise is ARCALYST (rilonacept), an IL-1 blocker approved for recurrent pericarditis (a painful inflammatory condition of the heart lining) that it commercializes in the US under a collaboration with Regeneron. ARCALYST drove roughly $677.5 million of net product revenue in 2025, up about 62% from 2024, and the company reported roughly $214.3 million in Q1 2026 (up about 56% year over year), leading management to raise full-year 2026 ARCALYST guidance to roughly $930 to $945 million.

Full KNSA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GLAS drivers: Low-cost greenhouse scale; Brands and retail as margin layers.
• KNSA drivers: ARCALYST adoption in recurrent pericarditis; Profitable growth profile.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is California wholesale cannabis pricing, which has been deeply depressed by oversupply and drove average selling prices and gross margin sharply lower, keeping the company unprofitable. For KNSA, the dominant risk is single-product concentration: essentially all revenue depends on ARCALYST in one indication, so any competitive entry, reimbursement pressure, safety signal, or eventual loss of exclusivity would be material.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GLAS if you believe its drivers more; KNSA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GLAS and KNSA guides.

GLAS. These are qualitative, approximate framings tied to the asOf date, not precise live figures; confirm current numbers before acting. Because Glass House is unprofitable and its results hinge on volatile California wholesale prices and uncertain federal policy, traditional earnings multiples say little. What matters most is the direction of selling prices, production volume, cost per pound, the mix shift toward retail and brands, and any movement on rescheduling. This is a speculative, catalyst-driven cannabis stock rather than a value-of-current-earnings play.

KNSA. As of July 2026, Kiniksa carried a market cap of roughly $5.2 billion against trailing revenue near $754 million and net income around $73 million, for a trailing P/E in the mid-70s. That multiple reflects both rare biotech profitability and expectations that ARCALYST keeps compounding toward the raised 2026 guidance of roughly $930 to $945 million.

Headline figures (approximate, Jul 2026): GLAS shows revenue trend Roughly $40.5 million in Q1 2026, down from about $44.8 million a year earlier; full-year 2026 guidance around $235 to $245 million. Wholesale biomass has been the majority of revenue. Approximate; verify live., profitability Unprofitable. Gross margin compressed to around 25% in Q1 2026 (versus roughly 45% a year earlier) and net losses deepened as selling prices fell and costs rose. Approximate; verify live., unit economics Average selling price around $171 per pound in Q1 2026, down from roughly $193 a year earlier, reflecting weak California wholesale pricing. Biomass production guided near 1,000,000 pounds for 2026. Approximate; verify live., balance sheet A scaling grower funding greenhouse expansion while losing money, so cash generation, debt, and potential dilution are worth watching closely. Verify current figures.; KNSA shows revenue (ttm) ~$754M, net income (ttm) ~$73M, market cap ~$5.2B, p/e (trailing) ~74x.

GLAS and KNSA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GLAS and KNSA exposure against your real portfolio. It is not an investment adviser.